Show source-provided references
2. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
10.3322/caac.21660 ↗4. High frequency of bone recurrence as an initial recurrence site after radical surgery in T1N3 gastric cancer: A propensity score matching analysis
10.1007/s00423-021-02231-8 ↗6. Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP)
10.1111/1759-7714.13272 ↗8. Ali, O.A., and Mooney, D.J. (2010). Immunologically active biomaterials for cancer therapy. Cancer Immunology and Immunotherapy, Springer.
10.1007/82_2010_69 ↗16. Synthesis and characterization of Barium-Iron containing magnetic bioactive glasses: The effect of magnetic component on structure and in vitro bioactivity
10.1016/j.colsurfb.2018.12.036 ↗17. Kermani, F., Kargozar, S., Dorozhkin, S.V., and Mollazadeh, S. (2022). Calcium phosphate bioceramics for improved angiogenesis. Biomaterials for Vasculogenesis and Angiogenesis, Woodhead Publishing.
10.1016/B978-0-12-821867-9.00004-4 ↗18. Calcium Phosphate-Based Bioceramics in the Treatment of Osteosarcoma: Drug Delivery Composites and Magnetic Hyperthermia Agents
10.3389/fmedt.2021.700266 ↗21. Mucalo, M. (2015). Structure and properties of hydroxyapatite for biomedical applications. Hydroxyapatite (Hap) for Biomedical Applications, Woodhead Publishing.
10.1016/B978-1-78242-033-0.00014-6 ↗24. Improved osteogenesis and angiogenesis of theranostic ions doped calcium phosphates (CaPs) by a simple surface treatment process: A state-of-the-art study
10.1016/j.msec.2021.112082 ↗25. Crystallization behavior and density functional theory study of solution combustion synthesized silicon doped calcium phosphates
10.1016/j.ceramint.2022.01.325 ↗26. Lara-Ochoa, S., Ortega-Lara, W., and Guerrero-Beltran, C.E. (2021). Hydroxyapatite Nanoparticles in Drug Delivery: Physicochemistry and Applications. Pharmaceutics, 13.
10.3390/pharmaceutics13101642 ↗28. Additive manufacturing methods for producing hydroxyapatite and hydroxyapatite-based composite scaffolds: A review
10.3389/fmats.2019.00313 ↗29. Biomimetic hollow mesoporous hydroxyapatite microsphere with controlled morphology, entrapment efficiency and degradability for cancer therapy
10.1039/C7RA09204K ↗30. Folate-modified hydroxyapatite nanorods induce apoptosis in MCF-7 cells through a mitochondrial-dependent pathway
10.1039/C9NJ03653A ↗32. 89Sr-doped hydroxyapatite nanoparticles as a potential therapeutic agent for bone tumors
10.1111/ijac.13262 ↗34. Doxorubicin loaded large-pore mesoporous hydroxyapatite coated superparamagnetic Fe3O4 nanoparticles for cancer treatment
10.1016/j.ijpharm.2016.05.046 ↗36. Luo, D., Xu, X., Iqbal, M.Z., Zhao, Q., Zhao, R., Farheen, J., Zhang, Q., Zhang, P., and Kong, X. (2021). siRNA-Loaded Hydroxyapatite Nanoparticles for KRAS Gene Silencing in Anti-Pancreatic Cancer Therapy. Pharmaceutics, 13.
10.3390/pharmaceutics13091428 ↗37. Folate conjugation improved uptake and targeting of porous hydroxyapatite nanoparticles containing epirubicin to cancer cells
10.1080/10837450.2020.1725045 ↗38. AbouAitah, K., Stefanek, A., Higazy, I.M., Janczewska, M., Swiderska-Sroda, A., Chodara, A., Wojnarowicz, J., Szałaj, U., Shahein, S.A., and Aboul-Enein, A.M. (2020). Effective Targeting of Colon Cancer Cells with Piperine Natural Anticancer Prodrug Using Functionalized Clusters of Hydroxyapatite Nanoparticles. Pharmaceutics, 12.
10.3390/pharmaceutics12010070 ↗40. Encapsulating doxorubicin-intercalated lamellar nanohydroxyapatite into PLGA nanofibers for sustained drug release
10.1016/j.cap.2019.08.003 ↗41. Hydroxyapatite-poly (vinyl alcohol) core-shell nanoparticles for dual delivery of methotrexate and gemcitabine for bone cancer treatment
10.1016/j.jddst.2019.03.041 ↗44. Hyaluronan-directed fabrication of co-doped hydroxyapatite as a dual-modal probe for tumor-specific bioimaging
10.1039/C9TB02787D ↗46. Hybrid Mesoporous Silica-Based Drug Carrier Nanostructures with Improved Degradability by Hydroxyapatite
10.1021/nn507485j ↗48. Selenium-substituted hydroxyapatite particles with regulated microstructures for osteogenic differentiation and anti-tumor effects
10.1016/j.ceramint.2019.04.075 ↗49. Mono-dispersed Ba2+-doped Nano-hydroxyapatite conjugated with near-infrared Cu-doped CdS quantum dots for CT/fluorescence bimodal targeting cell imaging
10.1016/j.microc.2017.05.003 ↗51. Radiosensitization induced by zinc-doped hydroxyapatite nanoparticles in breast cancer cells
10.1111/ijac.13707 ↗52. Quercetin-Loaded Luminescent Hydroxyapatite Nanoparticles for Theranostic Application in Monolayer and Spheroid Cultures of Cervical Cancer Cell Line In Vitro
10.1021/acsabm.1c00255 ↗53. Duality of iron (III) doped nano hydroxyapatite in triple negative breast cancer monitoring and as a drug-free therapeutic agent
10.1016/j.ceramint.2020.03.231 ↗56. Paduraru, A.V., Oprea, O., Musuc, A.M., Vasile, B.S., Iordache, F., and Andronescu, E. (2021). Influence of Terbium Ions and Their Concentration on the Photoluminescence Properties of Hydroxyapatite for Biomedical Applications. Nanomaterials, 11.
10.3390/nano11092442 ↗58. Magnetic hydroxyapatite: A promising multifunctional platform for nanomedicine application
10.2147/IJN.S147355 ↗61. Rare-earth (Gd3+, Yb3+/Tm3+, Eu3+) co-doped hydroxyapatite as magnetic, up-conversion and down-conversion materials for multimodal imaging
62. Gadolinium-Doped Hydroxyapatite Nanorods as T1 Contrast Agents and Drug Carriers for Breast Cancer Therapy
10.1021/acsanm.8b02036 ↗63. Synthesis, characterization and in vitro anti-cancer activity of vanadium-doped nanocrystalline hydroxyapatite
10.1039/C9NJ03406D ↗67. Nanoparticle Based Combination Treatments for Targeting Multiple Hallmarks of Cancer
68. Anti-osteosarcoma effect of hydroxyapatite nanoparticles both in vitro and in vivo by downregulating the FAK/PI3K/Akt signaling pathway
10.1039/D0BM00898B ↗69. Oxidative stress-induced apoptosis of osteoblastic MC3T3-E1 cells by hydroxyapatite nanoparticles through lysosomal and mitochondrial pathways
10.1039/C7RA01008G ↗70. Primary tumor and pre-metastatic niches co-targeting "peptides-lego" hybrid hydroxyapatite nanoparticles for metastatic breast cancer treatment
10.1039/C8BM00706C ↗72. Recent progress on fabrication and drug delivery applications of nanostructured hydroxyapatite
10.1002/wnan.1504 ↗79. Solution combustion synthesis (SCS) of theranostic ions doped biphasic calcium phosphates; kinetic of ions release in simulated body fluid (SBF) and reactive oxygen species (ROS) generation
10.1016/j.msec.2020.111533 ↗83. Defect-Related Luminescent Hydroxyapatite-Enhanced Osteogenic Differentiation of Bone Mesenchymal Stem Cells Via an ATP-Induced cAMP/PKA Pathway
10.1021/acsami.6b01103 ↗84. Natural polysaccharide-incorporated hydroxyapatite as size-changeable, nuclear-targeted nanocarrier for efficient cancer therapy
10.1039/D0BM01320J ↗86. Effect of hydroxyapatite particle size, morphology and crystallinity on proliferation of colon cancer HCT116 cells
10.1016/j.msec.2014.03.022 ↗87. The in vitro and in vivo anti-melanoma effects of hydroxyapatite nanoparticles: Influences of material factors
10.2147/IJN.S184792 ↗90. Luminescence enhanced Eu3+/Gd3+ co-doped hydroxyapatite nanocrystals as imaging agents in vitro and in vivo
10.1021/acsami.6b01814 ↗91. Eu/Tb codoped spindle-shaped fluorinated hydroxyapatite nanoparticles for dual-color cell imaging
10.1039/C6NR02137A ↗92. Different inhibitory effect and mechanism of hydroxyapatite nanoparticles on normal cells and cancer cells in vitro and in vivo
10.1038/srep07134 ↗93. Inhibitory effect comparison of the needle, spherical, and mesoporous hydroxyapatite nanoparticles on MCF-7 breast cancer cell line proliferation: An in vitro assay
94. Nanohydroxyapatite Exerts Cytotoxic Effects and Prevents Cellular Proliferation and Migration in Glioma Cells
10.1093/toxsci/kfz019 ↗95. Effect of hydroxyapatite nanoparticles on the ultrastructure and function of hepatocellular carcinoma cells in vitro
10.1088/1748-6041/1/1/006 ↗98. Mitochondria-Targeted Hydroxyapatite Nanoparticles for Selective Growth Inhibition of Lung Cancer in Vitro and in Vivo
10.1021/acsami.6b06094 ↗99. p53 reaction to apoptosis induced by hydroxyapatite nanoparticles in rat macrophages
10.1002/jbm.a.31892 ↗100. Differential cytotoxicity and particle action of hydroxyapatite nanoparticles in human cancer cells
10.2217/nnm.12.217 ↗